Structures of mGluRs shed light on the challenges of drug development of allosteric modulators

Current Opinion in Pharmacology

Volumn 20, Issue , 2015, Pages 1-7

  Bennett, Kirstie A ^a   Doré, Andrew S ^a   Christopher, John A ^a   Weiss, Dahlia R ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; DIPRAGLURANT; FENOBAM; G PROTEIN COUPLED RECEPTOR; GSK 221087; MAVOGLURANT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; QUISQUALIC ACID; RASEGLURANT; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DYSKINESIA; DYSTONIA; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR DOCKING; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; AGONISTS; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY;

ALLOSTERIC REGULATION; BINDING SITES; DRUG DESIGN; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84908159410     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.09.022     Document Type: Review

References (46)

1. N. Kunishima, Y. Shimada, Y. Tsuji, T. Sato, M. Yamamoto, T. Kumasaka, S. Nakanishi, H. Jingami, and K. Morikawa Structural basis of glutamate recoginition by a dimeric metabotropic glutamate receptor Nature 407 2000 971 977
2. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu Rev Pharmacol Toxicol 37 1997 205 237
3. H. Wu, C. Wang, K.J. Gregory, G.W. Han, H.P. Cho, Y. Xia, C.M. Niswender, V. Katritch, J. Meiler, and V. Cherezov Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric Modulator Science 344 2014 58 64
4. A. Doré, K. Okrasa, J. Patel, M. Serrano-Vega, K. Bennett, R. Cooke, J. Errey, A. Jazayeri, S. Khan, and B. Tehan Structure of a class C GPCR metabotropic glutamate receptor 5 transmembrane domain Nature 511 2014 557 562
5. C. Niswender, C. Jones, and P. Conn New therapeutic frontiers for metabotropic glutamate receptors Curr Top Med Chem 5 2005 847 857
6. S. Litschig, F. Gasparini, D. Rueegg, N. Stoehr, P.J. Flor, I. Vranesic, L. Prezeau, J.P. Pin, C. Thomsen, and R. Kuhn CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding Mol Pharmacol 55 1999 453 461
7. P. Malherbe, N. Kratochwil, M.T. Zenner, J. Piussi, C. Diener, C. Kratzeisen, C. Fischer, and R.H. Porter Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine Mol Pharmacol 64 2003 823 832
8. A. Pagano, D. Ruegg, S. Litschig, N. Stoehr, C. Stierlin, M. Heinrich, P. Floersheim, L. Prezèau, F. Carroll, and J.P. Pin The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J Biol Chem 275 2000 33750 33758
9. P.J. Flor, and F.C. Acher Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs Biochem Pharmacol 84 2012 414 424
10. 5 receptor antagonist Neuropharmacology 38 1999 1493 1503
11. B. Gomez-Mancilla, E. Berry-Kravis, R. Hagerman, F. von Raison, G. Apostol, M. Ufer, F. Gasparini, and S. Jacquemont Development of mavoglurant and its potential for the treatment of fragile X syndrome Expert Opin Investig Drugs 23 2014 125 134
12. D. Petrov, I. Pedros, M.L. de Lemos, M. Pallàs, A.M. Canudas, A. Lazarowski, C. Beas-Zarate, C. Auladell, J. Folch, and A. Camins Mavoglurant as a treatment for Parkinson's disease Expert Opin Investig Drugs 24 2014 1 15
13. O. Rascol, S. Fox, F. Gasparini, C. Kenney, T. Di Paolo, and B. Gomez-Mancilla Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias Parkinsonism Relat Disord 20 2014 947 956
14. 5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease Aliment Pharmacol Ther 33 2011 911 921
15. J.C. Marin, and P.J. Goadsby Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin Investig Drugs 19 2010 555 561
16. K.A. Emmitte mGlu5 negative allosteric modulators: a patent review (2010-2012) Expert Opin Ther Patents 23 2013 393 408
17. 5) negative allosteric modulator J Med Chem 57 2014 861 877
18. 5 ACS Chem Neurosci 2 2011 411 432
19. C.T.H. Friedmann, L.J. Davis, P.E. Ciccone, and R.T. Rubin Phase II double-blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo Curr Ther Res 27 1980 144 151
20. 5 receptor negative allosteric modulators Bioorg Med Chem Lett 23 2013 2134 2139
21. 5 positive allosteric modulators Bioorg Med Chem Lett 20 2010 7381 7384
22. 5 with activity in a mouse model of anxiety Bioorg Med Chem Lett 23 2013 5779 5785
23. 5 NAMs PAMs and partial antagonists Bioorg Med Chem Lett 21 2011 2711 2714
24. 5 allosteric modulators: highly potent positive and negative modulators from one chemotype Bioorg Med Chem Lett 21 2011 3407 3410
25. 5) J Med Chem 57 2014 5620 5637
26. C. Goudet, F. Gaven, J. Kniazeff, C. Vol, J. Liu, M. Cohen-Gonsaud, F. Archer, L. Perzeau, and J.P. Pin Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors Proc Natl Acad Sci USA 101 2004 378 383
27. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox, T. Le Trong, D.C. Teller, T. Okada, and R.E. Stenkamp Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745
28. K. Hollenstein, J. Kean, A. Bortolato, R.K. Cheng, A.S. Doré, A. Jazayeri, R.M. Cooke, M. Weir, and F.H. Marshall Structure of a class B corticotrophin-releasing factor receptor 1 Nature 499 2013 438 443
29. 1) antagonist Bioorg Med Chem Lett 19 2009 5464 5468
30. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci 25 1995 366 428
31. J.P. Pin, T. Galvez, and L. Prézeau Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors Pharmacol Ther 98 2003 325 354
32. K.P. Hofmann, P. Scheerer, P.W. Hildebrand, H.W. Choe, J.H. Park, M. Heck, and O.P. Ernst A G protein-coupled receptor at work: the rhodopsin model Trends Biochem Sci 34 2009 540 552
33. B.G. Tehan, A. Bortolato, F. Blaney, M.P. Weir, and J.S. Mason Unifying family A GPCR theories of activation Pharmacol Ther 143 2014 51 60
34. B. Wang, J.M. Vernier, S. Rao, J. Chung, J.J. Anderson, J.D. Brodkin, X. Jiang, M.F. Gardner, X. Yang, and B. Munoz Discovery of novel modulators of metabotropic glutamate receptor subtype-5 Bioorg Med Chem 12 2004 17 21
35. C. Bonnefous, J.M. Vernier, J.H. Hutchinson, M.F. Gardner, M. Cramer, J.K. James, B.A. Rowe, L.P. Daggett, H. Schaffhauser, and T.M. Kamenecka Biphenyl-indanones: allosteric potentiators of metabotropic glutamate subtype 2 receptor Bioorg Med Chem Lett 15 2005 4354 4358
36. 5 antagonist GSK2210875 Bioorg Med Chem Lett 20 2010 7521 7524
37. J.S. Mason, A. Bortolato, M. Congreve, and F.H. Marshall New insights from structural biology into the druggability of G protein coupled receptors Trends Pharmacol Sci 33 2012 249 260
38. J.S. Mason, A. Bortolato, D.R. Weiss, F. Deflorian, B. Tehan, and F.H. Marshall High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks In Silico Pharmacol 1 2013 1 12
39. (2A) antagonists as a case study J Chem Inf Model 53 2013 1700 1713
40. S. Sciabola, R.V. Stanton, J.E. Mills, M.M. Flocco, M. Baroni, G. Cruciani, F. Perruccio, and J.S. Mason High-throughput virtual screening of proteins using GRID molecular interaction fields J Chem Inf Model 50 2010 155 169
41. J.A. O'Brien, W. Lemaire, T.B. Chen, R.S. Chang, M.A. Jacobson, S.N. Ha, C.W. Lindsley, H.J. Schaffhauser, C. Sur, and D.J. Pettibone A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol Pharmacol 64 2003 731 740
42. 5) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology Mol Pharmacol 83 2013 991 1006
43. S.P. Andrews, G.A. Brown, and J.A. Christopher Structure-based and fragment-based GPCR drug discovery ChemMedChem 9 2014 256 275
44. 1-Adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design J Med Chem 56 2013 3446 3455
45. M. Congreve, C.J. Langmead, J.S. Mason, and F.H. Marshall Progress in structure based drug design for G protein-coupled receptors J Med Chem 54 2011 4283 4311
46. (2A) receptor antagonists by virtual screening J Med Chem 55 2012 1904 1909